Suppr超能文献

噻嗪类利尿剂与骨折风险:随机临床试验的系统评价与荟萃分析

Thiazide Diuretics and Fracture Risk: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

作者信息

Desbiens Louis-Charles, Khelifi Nada, Wang Yue-Pei, Lavigne Felix, Beaulieu Véronique, Sidibé Aboubacar, Mac-Way Fabrice

机构信息

CHU de Québec Research Center L'Hôtel-Dieu de Québec Hospital Quebec Canada.

Department of Medicine, Faculty of Medicine Laval University Quebec Canada.

出版信息

JBMR Plus. 2022 Oct 7;6(11):e10683. doi: 10.1002/jbm4.10683. eCollection 2022 Nov.

Abstract

Thiazide diuretics are commonly used antihypertensive agents. Until today, whether their use reduces fracture risk remains unclear. Our objective was to conduct a systematic review of thiazide diuretics' effects on fractures and bone mineral density (BMD) in randomized clinical trials (RCT) of adults. MEDLINE, EMBASE, CENTRAL, and the WHO's ICTRP registry were searched from inception to July 31, 2019. Two reviewers assessed studies for eligibility criteria: (i) RCTs; (ii) including adults; (iii) comparing thiazides, alone or in combination; (iv) to placebo or another medication; and (v) reporting fractures or BMD. Conference abstracts and studies comparing thiazides to antiresorptive or anabolic bone therapy were excluded. Bias was assessed using Cochrane Collaboration's Risk of Bias Tool-2. The primary outcome was fracture at any anatomical site. Secondary outcomes were osteoporotic fractures, hip fractures, and BMD at femoral neck, lumbar spine, and/or total hip. Fractures were pooled as risk ratios (RRs) using random-effect models. Prespecified subgroup analyses and post hoc sensitivity analyses were conducted. From 15,712 unique records screened, 32 trials (68,273 patients) met eligibility criteria. Thiazides were associated with decreased fractures at any site (RR = 0.87, 95% confidence interval [CI] 0.77-0.98;  = 0%) and osteoporotic fractures (RR = 0.80; 95% CI 0.69-0.94;  = 0%). Results were consistent in most subgroups and sensitivity analyses. Few studies reported hip fractures, and no association was found between thiazides and this outcome (RR = 0.84; 95% CI 0.67-1.04;  = 0%). Only four studies reported BMD; a meta-analysis was not conducted because BMD reporting was inconsistent. Trials were deemed at low (3 studies, weight = 3%), some concerns (16 studies; 71%), or high (11 studies; 26%) risk of bias for the primary outcome. In conclusion, thiazide diuretics decreases the risk of fractures at any and at osteoporotic sites in a meta-analysis of RCTs. Additional studies are warranted in patients with high fracture risk. © 2022 The Authors. published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

摘要

噻嗪类利尿剂是常用的抗高血压药物。迄今为止,其使用是否会降低骨折风险仍不明确。我们的目的是对成人随机临床试验(RCT)中噻嗪类利尿剂对骨折和骨密度(BMD)的影响进行系统评价。检索了MEDLINE、EMBASE、CENTRAL以及世界卫生组织国际临床试验注册平台(ICTRP),检索时间从建库至2019年7月31日。两名评价者根据纳入标准评估研究:(i)RCT;(ii)纳入成人;(iii)比较单独使用或联合使用的噻嗪类药物;(iv)与安慰剂或其他药物比较;(v)报告骨折或骨密度。会议摘要以及比较噻嗪类药物与抗吸收或促合成骨治疗的研究被排除。使用Cochrane协作网的偏倚风险工具-2评估偏倚。主要结局是任何解剖部位的骨折。次要结局是骨质疏松性骨折、髋部骨折以及股骨颈、腰椎和/或全髋部的骨密度。使用随机效应模型将骨折合并为风险比(RRs)。进行了预先设定的亚组分析和事后敏感性分析。在筛选的15712条独特记录中,32项试验(68,‍273例患者)符合纳入标准。噻嗪类药物与任何部位骨折风险降低相关(RR = 0.87,95%置信区间[CI] 0.77 - 0.98;I² = 0%)以及骨质疏松性骨折风险降低相关(RR = 0.80;95% CI 0.69 - 0.94;I² = 0%)。大多数亚组分析和敏感性分析结果一致。很少有研究报告髋部骨折,未发现噻嗪类药物与该结局之间存在关联(RR = 0.84;95% CI 0.67 - 1.04;I² = 0%)。只有四项研究报告了骨密度;由于骨密度报告不一致,未进行荟萃分析。对于主要结局,试验被认为偏倚风险低(3项研究,权重 = 3%)、有一些担忧(16项研究;71%)或高(11项研究;26%)。总之,在RCT的荟萃分析中,噻嗪类利尿剂降低了任何部位和骨质疏松部位的骨折风险。对于骨折风险高的患者,有必要进行更多研究。© 2022作者。由Wiley Periodicals LLC代表美国骨与矿物质研究学会出版。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13d2/9664541/8f8078cde3a2/JBM4-6-e10683-g004.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验